A state-of-the-art research and development facility, using world-class medical research to find solutions for a range of serious illnesses, has opened in West Auckland.
The A$50 million ($34.2 million) Douglas Innovation center is part of the long-established Douglas Pharmaceuticals company. The three-story, 4,500sq meter building has been 18 months in construction. It employs 100 people and includes a laboratory, pilot scale product development suites, commercial manufacturing rooms which can handle highly potent and cytotoxic products and office space.
Manufacturing capabilities include soft gelatine encapsulation, liquids, creams, and modified release oral dosage forms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze